Aditxt, INC. (ADTX) — SEC Filings

Overview

Aditxt, INC. (ADTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 22, 2026: Aditxt, Inc. filed an EFFECT form, indicating the effectiveness of a registration statement, on April 22, 2026. The filing, with SEC Accession No. 9999999995-26-001275, relates to Act 33 and File No. 333-295005. The company's mailing and business address is 737 N. FIFTH STREET, SUITE 200, RICHMOND V

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 5 bearish, 44 neutral, 1 mixed. The dominant filing sentiment for Aditxt, INC. is neutral.

Filing Type Overview

Aditxt, INC. (ADTX) has filed 1 EFFECT, 37 8-K, 1 S-3, 5 8-K/A, 2 DEF 14A, 3 10-Q, 1 S-1 with the SEC between Nov 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Aditxt, Inc. Registration Statement Declared Effective — EFFECT · Apr 22, 2026 Risk: medium
  Aditxt, Inc. filed an EFFECT form, indicating the effectiveness of a registration statement, on April 22, 2026. The filing, with SEC Accession No. 9999999995-26
• Aditxt, Inc. Enters New Material Agreement — 8-K · Apr 14, 2026 Risk: medium
  On April 14, 2026, Aditxt, Inc. filed an 8-K report detailing the entry into a material definitive agreement and the creation of a direct financial obligation.
• Aditxt Files S-3 Registration Statement — S-3 · Apr 11, 2026 Risk: medium
  Aditxt, Inc. filed an S-3 registration statement on April 13, 2026, with the SEC. This filing indicates the company's intent to register securities for future s
• Aditxt Amends Filing with Financials for Ignite Proteomics — 8-K/A · Apr 7, 2026 Risk: medium
  Aditxt, Inc. filed an amendment (8-K/A) on April 7, 2026, to its previous filing. This amendment includes audited financial statements for Ignite Proteomics LLC
• Aditxt, Inc. Files 8-K Report — 8-K · Apr 2, 2026 Risk: low
  On April 2, 2026, Aditxt, Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or significant business update
• Aditxt Seeks Shareholder Nod for Equity Issuances, Reverse Split, Name Change — DEF 14A · Dec 16, 2025 Risk: high
  Aditxt, Inc. (ADTX) is convening a Special Meeting on January 30, 2026, to address several critical proposals aimed at ensuring Nasdaq compliance and strategic
• 8-K Filing — 8-K · Dec 5, 2025
• Aditxt's Q3 Net Loss Widens to $24.2M Amid Revenue Collapse, Evofem Impairment — 10-Q · Nov 18, 2025 Risk: high
  Aditxt, Inc. (ADTX) reported a significant net loss of $24.21 million for the three months ended September 30, 2025, a substantial increase from the $6.98 milli
• Aditxt, Inc. Files 8-K: Rights, Bylaws, and Financials Updated — 8-K · Oct 31, 2025 Risk: medium
  On October 29, 2025, Aditxt, Inc. filed an 8-K report detailing material modifications to the rights of security holders and amendments to its articles of incor
• Aditxt, Inc. Terminates Material Definitive Agreement — 8-K · Oct 20, 2025 Risk: medium
  On October 20, 2025, Aditxt, Inc. reported the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the
• Aditxt, Inc. Enters Material Definitive Agreement — 8-K · Oct 3, 2025 Risk: medium
  On September 30, 2025, Aditxt, Inc. entered into a material definitive agreement. The company, formerly known as Aditx Therapeutics, Inc., is incorporated in De
• Aditxt, Inc. Reports on Security Holder Vote Matters — 8-K · Sep 24, 2025 Risk: medium
  Aditxt, Inc. filed an 8-K on September 24, 2025, reporting on a submission of matters to a vote of security holders. The filing does not contain specific detail
• Aditxt, Inc. Files 8-K: Material Agreement & Financial Obligation — 8-K · Sep 16, 2025 Risk: medium
  On September 12, 2025, Aditxt, Inc. entered into a material definitive agreement and incurred a direct financial obligation. The company also reported on unregi
• Aditxt, Inc. Enters Material Definitive Agreement — 8-K · Aug 27, 2025 Risk: medium
  On August 26, 2025, Aditxt, Inc. entered into a material definitive agreement. The company, previously known as Aditx Therapeutics, Inc., is incorporated in Del
• Aditxt, Inc. Files Amendment to Form 8-K — 8-K/A · Aug 18, 2025 Risk: low
  Aditxt, Inc. filed an amendment (No. 6) to its Form 8-K on August 18, 2025, related to financial statements and exhibits as of December 11, 2023. The company, f
• Aditxt's Revenue Plummets 98%, Net Loss Narrows Amid Cash Burn — 10-Q · Aug 14, 2025 Risk: high
  Aditxt, Inc. reported a net loss of $13,348,123 for the six months ended June 30, 2025, a significant improvement from the $22,492,573 net loss in the prior-yea
• Aditxt, Inc. Files 8-K: Regulation FD Disclosure & Exhibits — 8-K · Aug 11, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on August 11, 2025, reporting an event on August 6, 2025. The filing is a Regulation FD Disclosure and includes Financial Statements a
• Aditxt, Inc. Reports Board Changes and Shareholder Nominations — 8-K · Aug 8, 2025 Risk: medium
  Aditxt, Inc. announced on August 7, 2025, changes related to its board of directors and officers, including the election of new directors and potential changes
• Aditxt, Inc. Files 8-K Report — 8-K · Jul 24, 2025 Risk: low
  On July 22, 2025, Aditxt, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Financial Statements and Exhibits. No specific
• 8-K Filing — 8-K · Jul 21, 2025
• Aditxt, Inc. Files 8-K Report — 8-K · Jul 10, 2025 Risk: low
  On July 8, 2025, Aditxt, Inc. filed an 8-K report to disclose information under Regulation FD and to file financial statements and exhibits. The filing was made
• Aditxt, Inc. Files 8-K: Agreements, Obligations, and Equity Sales — 8-K · Jul 1, 2025 Risk: medium
  On June 26, 2025, Aditxt, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on the creat
• Aditxt, Inc. Reports Material Agreement and Equity Sales — 8-K · Jun 25, 2025 Risk: medium
  On June 20, 2025, Aditxt, Inc. entered into a material definitive agreement, likely related to its operations in the pharmaceutical preparations sector. The com
• Aditxt Files S-1 for Continuous Offering, Signaling Future Capital Raise — S-1 · Jun 20, 2025 Risk: high
  Aditxt, Inc. (ADTX) filed an S-1 registration statement on June 20, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a potent
• Aditxt, Inc. Files 8-K: Agreements, Financing, and Officer Changes — 8-K · Jun 9, 2025 Risk: medium
  On June 5, 2025, Aditxt, Inc. entered into a material definitive agreement, likely related to financing or operations, as indicated by the filing of an 8-K. The
• Aditxt, Inc. Files 8-K Report — 8-K · Jun 2, 2025 Risk: low
  On May 30, 2025, Aditxt, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Financial Statements and Exhibits. No specific f
• Aditxt, Inc. Raises $1M via Stock Sale — 8-K · May 27, 2025 Risk: medium
  On May 22, 2025, Aditxt, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement with an investor. This agreement result
• Aditxt, Inc. Files 8-K Amendment with Updated Financials — 8-K/A · May 19, 2025 Risk: low
  Aditxt, Inc. filed an amendment (Amendment No. 5) to its Form 8-K on December 11, 2023, to provide updated financial statements and exhibits. This filing relate
• Aditxt, Inc. Files Q1 2025 10-Q Report — 10-Q · May 15, 2025 Risk: low
  Aditxt, Inc. filed its 10-Q report for the quarterly period ended March 31, 2025. The company, formerly known as Aditx Therapeutics, Inc., is incorporated in De
• Aditxt, Inc. Files 8-K Current Report — 8-K · May 5, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on May 5, 2025, reporting an event on May 2, 2025. The filing is a current report under Regulation FD and includes financial statement
• Aditxt, Inc. Files 8-K: Agreements, Obligations, and Equity Sales — 8-K · Apr 25, 2025 Risk: medium
  On April 24, 2025, Aditxt, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on the crea
• Aditxt, Inc. Files 8-K Current Report — 8-K · Apr 22, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on April 22, 2025, reporting an event on April 18, 2025. The filing is a current report under Regulation FD and includes financial sta
• Aditxt, Inc. Files 8-K on Security Holder Votes — 8-K · Apr 17, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on April 17, 2025, reporting on the submission of matters to a vote of security holders. The company, formerly known as Aditx Therapeu
• Aditxt, Inc. Signs Material Definitive Agreement — 8-K · Apr 15, 2025 Risk: medium
  On April 10, 2025, Aditxt, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreeme
• Aditxt, Inc. Relocates Principal Executive Offices — 8-K · Apr 14, 2025 Risk: low
  On April 11, 2025, Aditxt, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2569 Wyandotte Street, Suite
• Aditxt, Inc. Files 8-K for Other Events — 8-K · Apr 9, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on April 9, 2025, reporting other events and financial statements as of April 8, 2025. The company, formerly known as Aditx Therapeuti
• Aditxt, Inc. Files 8-K with Regulatory Disclosures — 8-K · Apr 7, 2025 Risk: low
  On April 4, 2025, Aditxt, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Ad
• Aditxt, Inc. Files 8-K with Financials and Exhibits — 8-K · Mar 31, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on March 31, 2025, reporting events as of March 28, 2025. The filing indicates a Regulation FD Disclosure and includes Financial State
• Aditxt, Inc. Files 8-K for Other Events and Exhibits — 8-K · Mar 28, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on March 28, 2025, reporting an event that occurred on March 24, 2025. The filing pertains to financial statements and exhibits, and o
• Aditxt, Inc. Files Amendment to 8-K — 8-K/A · Mar 25, 2025 Risk: low
  Aditxt, Inc. filed Amendment No. 4 to its Form 8-K on March 25, 2025, to correct and supplement information regarding its financial statements and exhibits. The
• Aditxt, Inc. Files 8-K Report — 8-K · Mar 24, 2025 Risk: low
  On March 21, 2025, Aditxt, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or disclo
• Aditxt, Inc. Relocates Principal Executive Offices — 8-K · Mar 17, 2025 Risk: low
  On March 17, 2025, Aditxt, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2569 Wyandotte Street, Suite
• Aditxt Faces Delisting Concerns, Filing Reveals Listing Rule Issues — 8-K · Mar 12, 2025 Risk: high
  Aditxt, Inc. filed an 8-K on March 12, 2025, reporting events as of March 7, 2025. The filing indicates a notice of delisting or failure to meet continued listi
• Aditxt, Inc. Enters Material Definitive Agreement — 8-K · Mar 6, 2025 Risk: medium
  On March 5, 2025, Aditxt, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as Aditx Therap
• Aditxt, Inc. Files 8-K on Security Holder Votes and Other Events — 8-K · Mar 3, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on March 3, 2025, reporting on events that occurred on February 28, 2025. The filing indicates a submission of matters to a vote of se
• Aditxt, Inc. Files 8-K Report — 8-K · Feb 24, 2025 Risk: low
  On February 21, 2025, Aditxt, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD Disclosure. No spec
• Aditxt, Inc. Files Definitive Proxy Statement — DEF 14A · Jan 27, 2025 Risk: low
  Aditxt, Inc. filed its definitive proxy statement (DEF 14A) on January 27, 2025, for its fiscal year ending December 31, 2024. The filing pertains to the compan
• Aditxt, Inc. Files 8-K for Jan 13, 2025 — 8-K · Jan 13, 2025 Risk: low
  Aditxt, Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Aditx
• Aditxt, Inc. Files 8-K with Financials and Exhibits — 8-K · Dec 12, 2024 Risk: low
  On December 11, 2024, Aditxt, Inc. filed an 8-K report to disclose information under Regulation FD. The filing also includes financial statements and exhibits.
• Aditxt, Inc. Files 8-K Amendment — 8-K/A · Nov 21, 2024 Risk: low
  Aditxt, Inc. filed an amendment (Amendment No. 3) to its Form 8-K on November 21, 2024, reporting events that occurred on April 1, 2024. The filing pertains to

Risk Profile

Risk Assessment: Of ADTX's 48 recent filings, 5 were flagged as high-risk, 18 as medium-risk, and 25 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Aditxt, INC.'s most recent 10-Q filing (Nov 18, 2025):

• Revenue: $748
• Net Income: -$24.21M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $163,041
• Operating Margin: N/A
• Total Assets: $11.80M
• Total Debt: N/A

Key Executives

• Amro Albanna
• Thomas J. Farley
• Christopher J. Porcelli
• Richard A. Friedman, Esq.
• Sean F. Reid, Esq.

Industry Context

Aditxt operates in the biotechnology and diagnostics sector, a highly competitive and rapidly evolving industry. Companies in this space often rely on significant capital investment for research and development, and face stringent regulatory hurdles. Success is frequently tied to the ability to secure funding, achieve clinical milestones, and navigate complex intellectual property landscapes. The current market sentiment for many small-cap biotech firms can be volatile, influenced by trial results, regulatory approvals, and broader economic conditions.

Top Tags

material-agreement (10) · 8-K (10) · exhibits (9) · financial-statements (7) · amendment (5) · filing (5) · financial-obligation (5) · equity-sale (5) · disclosure (5) · sec-filing (4)

Key Numbers

• Effectiveness Date: 2026-04-22 — The date the SEC accepted the filing, indicating the registration statement is now effective.
• File Number: 333-295005 — The specific SEC file number associated with this registration statement.
• Filing Date: 2026-04-13 — Date Aditxt, Inc. filed its S-3 registration statement
• Financial Statement Date: December 31, 2025 — Audited financial statements for Ignite Proteomics LLC are as of this date.
• Pro Forma Period: 2025 — Unaudited pro forma consolidated financial information is for the year ended this year.
• Proposed increase in shares for 2021 Omnibus Equity Incentive Plan: 350,000 shares — Increased from 3 shares, indicating a significant expansion of employee incentives.
• Range for proposed reverse stock split ratio: 1:5 to 1:250 — Indicates a wide potential adjustment to share price, reflecting significant volatility or low stock price.
• Issuance date of Series A-1 Convertible Preferred Stock: December 2023 — Relevant for Nasdaq compliance proposal.
• Issuance dates of Series C-1 Convertible Preferred Stock and warrants: May 2024 and August 2024 — Relevant for Nasdaq compliance proposal.
• Issuance date of common stock purchase warrants: July 2024 — Relevant for Nasdaq compliance proposal.
• Date of Special Meeting of Stockholders: January 30, 2026 — When all proposals will be voted on.
• Record Date for voting eligibility: December 5, 2025 — Determines which stockholders can vote at the Special Meeting.
• Common stock outstanding on Record Date: 1,776,023 shares — Total shares eligible to vote at the Special Meeting.
• Shares required for a quorum: 592,008 shares — One-third of outstanding shares needed to conduct business at the Special Meeting.
• Net Loss (Q3 2025): $24.21M — Increased from $6.98M in Q3 2024, indicating worsening financial performance.

Related Companies

EVFM

Frequently Asked Questions